Highlights Johnson & Johnson Deutsche Boerse AG

Equities

JNJ

US4781601046

Market Closed - Deutsche Boerse AG Other stock markets 11:03:56 2024-07-16 am EDT			5-day change	1st Jan Change
138.1 ^EUR	+1.31%		+1.54%	-2.51%

Jul. 16	ORIC Pharmaceuticals, Inc. Enters into Clinical Trial Collaboration and Supply Agreements with Bayer and Janssen Research & Development, LLC	CI
Jul. 16	EQT Unit Invests in Biotechnology Company Asceneuron	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

ORIC Pharmaceuticals, Inc. Enters into Clinical Trial Collaboration and Supply Agreements with Bayer and Janssen Research & Development, LLC	Jul. 16	CI
EQT Unit Invests in Biotechnology Company Asceneuron	Jul. 16	MT
Equity Markets Higher After Fed Chair Powell's Comments	Jul. 15	MT
Equity Markets Rise Intraday After Fed Chair Powell's Comments	Jul. 15	MT
Stocks Gain Pre-Bell Ahead of Key Earnings; Asia Mixed, Europe Down	Jul. 15	MT
Brace for a flurry of speeches from Fed officials	Jul. 15
J&J: completes acquisition of Yellow Jersey for $1.25 billion	Jul. 12	CF
Johnson & Johnson Completes Acquisition of Yellow Jersey Therapeutics	Jul. 11	MT
Mixed feelings	Jul. 09
Emergent Biosolutions, Johnson & Johnson Settle Dispute Over COVID-19 Vaccine Manufacturing	Jul. 09	MT
Indivior shares dive on profit warning, dropping of schizophrenia drug (July 9)	Jul. 09	RE
Emergent, J&J settle COVID vaccine supply deal dispute	Jul. 08	RE
Emergent Biosolutions to Get $50 Million from Covid-19 Manufacturing Settlement with Johnson & Johnson Unit	Jul. 08	DJ
Stryker Corporation : Major Player in Medical Devices	Jul. 05
J&J: promising results in multiple myeloma	Jul. 02	CF
Johnson & Johnson Says Interim Analysis of Blood Cancer Therapy Study Show Promise	Jul. 02	MT
Johnson & Johnson Announces Positive Results from Prespecified Second Interim Analysis of the Phase 3 CARTITUDE-4 Study Evaluating CARVYKTI	Jul. 02	CI
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	Jun. 28	MT
J&J Unit's Rybrevant Combo Gets EU Approval	Jun. 28	MT
Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study	Jun. 28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST